

AMENDMENTS

In the specification:

Please add an abstract according to the separate sheet attached hereto.

In the claims:

Please cancel claims 9-15.

Please amend the claims as follows:

- A²
1. (Once Amended) A pharmaceutical preparation for treating rheumatic syndromes comprising: sulfur, mustard seed and a cupric salt.
 2. (Once Amended) The pharmaceutical preparation of claim 1, wherein the cupric salt is copper sulfate.
 3. (Once Amended) The pharmaceutical preparation of claim 2 further comprising chamomile.
 4. (Once Amended) The pharmaceutical preparation of claim 3 further comprising talc as a carrier substance.
 5. (Once Amended) The pharmaceutical preparation of claim 4 further comprising camphor.
 6. (Once Amended) The pharmaceutical preparation of claim 5 further comprising potassium iodate.

7. (Once Amended) The pharmaceutical preparation of claim 1, wherein the preparation is in powder form.

8. (Once Amended) The pharmaceutical preparation of claim 1 comprising the following volume concentrations:

A²
cont.

sulfur:	30-50% by weight;
camomile:	0-10% by weight;
camphor:	0-25% by weight;
mustard seed:	0.5-2.5% by weight;
copper sulfate:	0.05-0.3% by weight;
potassium iodate:	0-0.15% by weight; and
talc making up the remainder up to 100% by weight.	

Please add the following new claims:

A³

16. A pharmaceutical preparation of claim 3, wherein the chamomile is chamomile flowers.

17. A process for producing a pharmaceutical preparation useful for the treatment of rheumatic syndromes, wherein the process comprises the steps of:

mixing components comprising talc and sulfur into a powder form; and
adding catalytic powder to the powder form;

wherein the catalytic powder is a pulverulent mixture comprising talc, mustard seed and copper sulfate.

- A3
cont
18. The process of claim 17 wherein the components further comprise camphor.
 19. The process of claim 18 wherein the components further comprise chamomile.
 20. The process of claim 19, wherein the chamomile is chamomile flowers.
 21. The process of claim 17, wherein the catalytic powder further comprises potassium iodate.
 22. The process of claim 17, further comprising the step of blending the components and the catalytic powder.
 23. A pharmaceutical preparation produced by claim 17, wherein the preparation is adapted to treat rheumatic syndromes.
 24. A method for treating a disorder, wherein said method comprises the step of administering to a human the pharmaceutical preparation of claim 1, and wherein the disorder is sciatica, muscular rheumatism, arthritis, phlebitis, excessively high or low blood pressure, paralysis deformans, paralysis post myelitis, poliomyelitis, paralysis cerebrealis, paralysis post nephritis vel uraemia, paralysis postlaesion cause alicuia mechanica, eczema, or x-ray-induced burns.

25. A method of claim 24, further comprising the step of cutaneously administering the pharmaceutical preparation.

A3
CONT.
26. The method of claim 24, wherein the pharmaceutical preparation is in the form of a powder suitable for application on a sole of a foot.

27. The pharmaceutical preparation of claim 8, wherein the sulfur is present in a volume concentration of 30-40% by weight, and wherein the camomile is present in a volume concentration of 5-10% by weight, and wherein the camphor is present in a volume concentration of 15-25% by weight, and wherein the mustard seed is present in a volume concentration of 1-1.5% by weight, and wherein the copper sulfate is present in a volume concentration of 0.1-0.15% by weight, and wherein the potassium iodate is present in a volume concentration of 0.05-0.1% by weight.

REMARKS

Specification

Applicant has provided an abstract for the specification, according to the Examiner's observation.

Claim Objection under 37 CFR 1.75(c)

Claims 1-8 have been amended so as to conform with the Examiner's observations under 37 CFR 1.75(c). Claims 9-15 have been cancelled.